Anti-KRAS Polyclonal Antibody

Name: Anti-KRAS Polyclonal Antibody
Brand: TargetMol
SKU: TMAB-01034
Rating: 4.5 (1 reviews)

(Synonyms: RASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2) Copy Product Info

🥰Excellent

Synonyms: RASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2

Catalog No. TMAB-01034 Copy Product Info

🥰Excellent

Anti-KRAS Polyclonal Antibody is a Rabbit antibody targeting KRAS. Anti-KRAS Polyclonal Antibody can be used in FCM, IF, IHC-Fr, IHC-P, WB.

Anti-KRAS Polyclonal Antibody

Pack Size	Price	USA Stock	Global Stock
50 μL	$222	7-10 days	7-10 days
100 μL	$374	7-10 days	7-10 days
200 μL	$527	7-10 days	7-10 days

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Resource Download

Instruction Manual of Detection Antibody

Product Introduction

Bioactivity

Description	Anti-KRAS Polyclonal Antibody is a Rabbit antibody targeting KRAS. Anti-KRAS Polyclonal Antibody can be used in FCM, IF, IHC-Fr, IHC-P, WB.
Synonyms	RASK2, RALD, NS3, NS, K-RAS4B, K-RAS4A, K-RAS2B, K-RAS2A, KRAS2, KRAS1, K-RAS, Kirsten rat sarcoma viral oncogene homolog, KI-RAS, C-K-RAS, CFC2
Ig Type	IgG
Reactivity	Human,Mouse,Rat

Application	FCM IF IHC-Fr IHC-P WB
Recommended Dose	FCM=1 μg/Test; IF=1:100-500; IHC-Fr=1:100-500; IHC-P=1:100-500; WB=1:500-2000
Antibody Type	Polyclonal
Host Species	Rabbit
Subcellular Localization	Cell membrane. Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus. Golgi apparatus membrane; Lipid-anchor. Isoform 2: Nucleus. Cytoplasm. Cytoplasm, perinuclear region.
Tissue Specificity	Widely expressed.
Construction	Polyclonal Antibody
Purification	Protein A purified
Appearance	Liquid
Formulation	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Concentration	1 mg/mL
Research Background	This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq] Ras, a proto-oncogene, is a small G-protein that has 3 primary isoforms (H-Ras, N-Ras, and K-Ras) that differ in there approximately 20 C-terminal amino acids. H-Ras was first discovered as a transforming product the retrovirus Harvey murine virus and K-Ras of Kirten sarcoma virus. Ras is a heavily studied target of both academic and pharmaceutical research because of its implications in various pathways and diseases as well as being mutated in a large number of human cancers. Ras is most notably the activator of the Erk/MAPK kinase pathway as activator of Raf, as well as an activator of PI3 Kinase (PI3K). In its oncogenic, mutated state, Ras is unable to hydrolyze GTP to GDP, thus staying in an active state and activating numerous pathways including the MAPK pathway through its activation of Raf, but also others as well that include PI3 Kinase and RalGDS. One path that the pharmaceutical industry has taken to control Ras and its activity is by finding what some consider its Achilles’ heel. For its activation, Ras must localize to the plasma membrane, but interestingly, it lacks a transmembrane domain. To achieve this, Ras must first undergo a post-translational modification (PTM) known as prenylation or geranylation at its C-terminal CAAX motif. For this to take place, a controlled three step process must occur. The first step in the process is the prenylation or geranylation of the C in the CAAX motif that is initiated by the covalent attachment of farnesyl groups to the cysteine that is catalyzed by the . After this modification, the and heterodimer enzymes farnesyl transferases –aaX of the motif is proteolytically removed via Rce1 (Ras Converting Enzyme 1), a membrane associated endoprotease, by a mechanism that is still not fully understood. Finally, the C-terminal prenylcysteine is now methlylated by ICMT (Isoprenylcysteine Carboxymethyl Transferase). These drugs have yet to pass clinical trials though and there is doubt that they will ever be successful in treating tumors associated with Ras activation.

Antigen Details

Immunogen	KLH conjugated synthetic peptide: human K-ras
Antigen Species	Human
Gene Name	KRAS
Gene ID	3845
Protein Name	GTPase KRas
Uniprot ID	P01116
Biology Area	Ras family,Proto-oncogenes,Ras Family
Function	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.